Valuation: Grace Therapeutics, Inc.

Market Cap 62.01M 45.02M 38.54M 35.96M 33M 4.31B 63.23M 427M 166M 2.16B 169M 165M 7.15B P/E 2027 *
-1.77x
P/E 2028 * -4.61x
Enterprise Value 62.01M 45.02M 38.54M 35.96M 33M 4.31B 63.23M 427M 166M 2.16B 169M 165M 7.15B EV / Sales 2027 *
-
EV / Sales 2028 * 9.06x
Free-Float
81.8%
Yield 2027 *
-
Yield 2028 * -
1 day-2.73%
1 week+3.38%
Current month+2.88%
1 month-11.93%
3 months-1.83%
6 months-44.85%
Current year-38.15%
1 week 2.04
Extreme 2.04
2.25
1 month 1.85
Extreme 1.85
2.44
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
23.13
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 04/04/2023
Director of Finance/CFO 55 05/01/2024
Chief Tech/Sci/R&D Officer 65 08/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 04/04/2023
Director/Board Member 59 10/10/2023
Date Insider Type Main position Quantity % Market Cap.
14/08/26
Opaleye Management, Inc.
BuyCompany 11,608 0.0713%
12/01/26 Option

Chairman

10,000 0.0646%
12/01/26 Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-2.73%+3.38%-34.56%-0.93% 45.02M
+2.38%+3.43%+82.88%+115.89% 73.96B
-0.32%+20.84%+53.19%+93.47% 64.66B
-4.27%-0.99%-3.38%+475.61% 27.32B
-1.97%+20.38%-0.37%+0.48% 27.86B
+2.74%+12.98%+62.84%+28.14% 25.97B
-0.61%+5.08%+35.32%-14.63% 19.98B
-1.79%-4.84%+239.54%+414.48% 17.84B
+0.94%+3.36%+18.55%+532.94% 16.24B
-1.29%+6.09%+41.81%+154.45% 13.3B
Average -0.46%+5.90%+49.58%+179.99% 28.72B
Weighted average by Cap. +0.25%+8.21%+58.97%+160.75%

Financials

2027 *2028 *
Net sales - 6.84M 4.97M 4.25M 3.97M 3.64M 475M 6.98M 47.07M 18.35M 238M 18.65M 18.24M 788M
Net income -34.73M -25.21M -21.59M -20.14M -18.48M -2.41B -35.41M -239M -93.15M -1.21B -94.67M -92.61M -4B -16.92M -12.28M -10.52M -9.81M -9M -1.18B -17.25M -116M -45.37M -589M -46.12M -45.11M -1.95B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
20/08/26 $2.140 -2.73% 54,720
19/08/26 $2.200 +3.29% 159,756
18/08/26 $2.130 -1.39% 103,940
17/08/26 $2.160 0.00% 99,356
14/08/26 $2.160 +4.35% 397,808
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.948CAD
Average target price
8.342CAD
Spread / Average Target
+183.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock